In this context, GLP-1 RA has been proposed in condition of non-diabetes hyperglycemia to rule out possible confounders,—mainly cardiovascular burden and concomitant anti diabetes therapies—, which may have pointed to a novel clinical application of GLP-1 RA in MCI, targeting outcomes other than glucose control. This evidence concerns the gene GCG and diabetes mellitus.